Camrelizumab Uses, Dosage, Side Effects and more
Camrelizumab is under investigation in clinical trial NCT03417895 (SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy).
| Attribute | Details |
|---|---|
| Trade Name | Camrelizumab |
| Generic | Camrelizumab |
| Camrelizumab Other Names | Camrelizumab |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
